Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > TOP STORIES
TOP STORIES
-
ORGANIZATION Chuikyo Rep Interview 3-2 - Rengo Wants Substantive Discussions on Pricing System, Off-Year Revisions over Next Few Years
October 26, 2023
-
BUSINESS With Wholesalers Narrowed Down, Hospitals Face Squeezed Discounts for GSK Products
October 25, 2023
-
ORGANIZATION Chuikyo Rep Interview 3-1 - Rengo Seeks Patient-Centric Debate, Sees Exhausted Wholesalers as Big Issue
October 25, 2023
-
BUSINESS Sawai Fudged Quality Tests of Gastritis Drug for 8 Years, Awaiting Penalty Decision
October 24, 2023
-
BUSINESS Daiichi Sankyo, Merck in Global ADC Deal Worth Up to US$22 Billion
October 23, 2023
-
REGULATORY Chuikyo Wants Sakigake Premium Review as a Package with Regulatory Reform
October 23, 2023
-
BUSINESS Medicon, Mucodyne among Drugs Subject to MHLW’s Ramp-Up Request
October 20, 2023
-
BUSINESS Oncology, Cell & Gene Therapies Key Priorities for Bayer Co.Labs: Global Head
October 20, 2023
-
REGULATORY China Formally Arrests Astellas Employee, Japan Urges Immediate Release
October 20, 2023
-
REGULATORY Japan to Buy 10 Million More Doses of Pfizer/Moderna COVID Jabs
October 19, 2023
-
REGULATORY Health Minister Requests 8 Makers to Bolster Supplies of Antitussive, Expectorant Agents
October 19, 2023
-
REGULATORY Chuikyo at Odds over Handling of Startups in PMP, Timing of Deferred Price Cuts
October 19, 2023
-
BUSINESS BMS Looks to Double Japan Biz in Next 10 Years with Partnership as a Pillar
October 19, 2023
-
REGULATORY Average Price Gap for 2024 Revision Looks to Be Lower than 7.0%: Wholesalers
October 18, 2023
-
BUSINESS IBM Leads Development of Integrated Drug Supply Database for Wholesaler Reps, Pharmacists
October 18, 2023
-
REGULATORY AMED Group to Draft Master Protocols Guidelines by March-End, Frets Further Drug Lag/Loss
October 17, 2023
-
REGULATORY Health Minister Laments Drug Lag/Loss, Stresses Need for Govt-Driven Innovation Ecosystem
October 16, 2023
-
REGULATORY MHLW Regulatory Panel OKs New Procedures for Post-Approval Manufacturing Changes
October 16, 2023
-
BUSINESS Shonan iPark Looks to Woo Korean Firms by Partnering with Govt: Chief
October 13, 2023
-
ORGANIZATION Chuikyo Rep Interview 2-3 - With 80% Generic Share, Now Is the Time to Revisit LLP Copay, Says Payer Rep
October 13, 2023
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…